Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01695122
Recruitment Status : Completed
First Posted : September 27, 2012
Last Update Posted : February 23, 2016
University of Sao Paulo
Information provided by (Responsible Party):
Milena Mak, Instituto do Cancer do Estado de São Paulo

Brief Summary:
The purpose of this study is to evaluate if the addition of valproic acid to standard platinum-based chemoradiation as definitive treatment of locally advanced Head and Neck squamous cell carcinoma can improve treatment outcomes, such as response rate.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Oral Cavity Cancer Oropharyngeal Cancer Drug: Valproic Acid Phase 2

Detailed Description:

Valproic acid is a known histone deacetylase inhibitor. In addition to activating apoptosis pathways, cell differentiation and downregulating expression of growth factors, it also promotes radiosensitization.

Most patients with Head and Neck squamous cell carcinoma are diagnosed with locally advanced disease, in which long term disease control is still a challenge. The incorporation of epigenetic regulation into standard treatment could improve results of definitive platinum-based chemoradiation in such patients.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
Study Start Date : September 2012
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Arm Intervention/treatment
Experimental: valproic acid Drug: Valproic Acid
Other Name: sodium valproate

Primary Outcome Measures :
  1. Response Rate [ Time Frame: Within 6 to 8 weeks after completion of chemoradiation ]
    RECIST v 1.1

Secondary Outcome Measures :
  1. Adverse reactions to study treatment
  2. Progression free survival [ Time Frame: Three years ]
  3. Overall survival [ Time Frame: Three Years ]
  4. Response rate comparison by p16 status
  5. Quality of life

Other Outcome Measures:
  1. Biomarkers assessment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Unresectable Oropharyngeal or oral cavity squamous cell carcinoma
  • Candidate for definitive chemoradiation
  • No previous treatment
  • Measurable disease according to RECIST v 1.1
  • Previous neoplasia, other than Head and Neck, with more than five years without evidence of disease; basocellular carcinoma of the skin and in situ cervical dysplasia if resected
  • Age under 60 years
  • ECOG performance status 0-2
  • Ability of understanding and giving informed consent
  • Adequate renal and hepatic function
  • Adequate bone marrow function
  • Normal serum magnesium
  • Absence of QTc prolongation
  • Life expectancy of over 12 weeks

Exclusion Criteria:

  • Pregnancy
  • Distant metastasis
  • Hypersensibility to valproic acid or other antiepileptic drugs
  • Valproic acid chronic use
  • Severe neurologic impairment
  • Uncontrolled comorbidity
  • Hypoalbuminemia
  • Known history of hepatitis B, C or HIV

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01695122

Instituto do Cancer do Estado de Sao Paulo
Sao Paulo, SP, Brazil, 05409-011
Sponsors and Collaborators
Instituto do Cancer do Estado de São Paulo
University of Sao Paulo
Principal Investigator: Milena P Mak, MD Instituto do Cancer do Estado de Sao Paulo - University of Sao Paulo

Responsible Party: Milena Mak, MD, Instituto do Cancer do Estado de São Paulo Identifier: NCT01695122     History of Changes
Other Study ID Numbers: 327/11
First Posted: September 27, 2012    Key Record Dates
Last Update Posted: February 23, 2016
Last Verified: February 2016

Keywords provided by Milena Mak, Instituto do Cancer do Estado de São Paulo:
Head and Neck Cancer
Oropharyngeal cancer
Oral cavity cancer
valproic acid
histone deacetylase

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Oropharyngeal Neoplasms
Mouth Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Neoplasms by Site
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Mouth Diseases
Valproic Acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs